期刊文献+

131I清除分化型甲状腺癌术后残留腺体的内照射吸收剂量与疗效的分析 被引量:8

Relationship between internal radiation dose and outcome of radioiodine ablation of differentiated thyroid cancer
原文传递
导出
摘要 目的 探讨131I清除DTC术后残留甲状腺组织(简称清甲)的内照射吸收剂量与疗效的相关性.方法 前瞻性分析2009年9月至2011年9月拟行清甲的72例DTC患者[男14例,女58例,年龄16~67(41±16)岁].在患者服用3.7 GBq 131I后采用连续显像法评估残留腺体的碘代动力学,利用超声测量残留腺体的质量,按照美国核医学会医用内照射剂量学委员会提出的内照射吸收剂量计算方法,计算残留腺体的吸收剂量.清甲治疗后6~9个月,判断疗效:若刺激状态下Tg<l μg/L及颈部超声检查提示甲状腺床区无腺体组织残留,判断为清甲成功.清甲成功与未成功者组间比较采用两样本t检验.结果 72例患者的残留腺体24h摄碘率为0.9%~6.3%, 131I有效半衰期为12.0~146.4 h,腺体质量为1.0~6.9g,吸收剂量为23~2 197 Gy,24 h吸收剂量率为0.5~8.1 Gy/h.43例清甲成功者与29例清甲未成功者残留腺体的吸收剂量分别为(363±148) Gy和(341±167) Gy,差异无统计学意义(£=15.097,P>0.05);24 h吸收剂量率分别为(3.7±2.1) Gy/h和(2.9±1.6) Gy/h,差异有统计学意义(t=7.908,P<0.05).结论 131I清甲残留腺体的吸收剂量率影响清甲疗效. Objective To investigate the relationship between the absorbed dose to the thyroid remnant and the outcome of m I ablation in patients after operation for DTC.Methods Seventy-two patients (14 males,58 females; age range:16-67 years,average age:(41±16) years) with DTC,prepared for thyroid remnant ablation,were prospectively recruited from September 2009 to September 2011.Scintigraphic images of the head and neck were serially acquired after oral administration of 3.7 GBq of 131I to assess the biokinetics of this tracer in thyroid remnant.Ultrasound was used to measure the mass of the thyroid remnant.Calculation of absorbed dose to thyroid remnant was based on the Medical Internal Radiation Dosimetry formula of the Society of Nuclear Medicine.The outcome of 131 I ablation was evaluated on the basis of stimulated Tg measurements and neck ultrasound at 6-9 months after ablation.Patients with stimulated Tg levels less than 1 μg/L and with no detectable thyroid tissue on neck ultrasound were considered successful ablation of thyroid remnant.Two-sample t test was used to analyze the data.Results The 131I uptake ratios at 24 h were 0.9%-6.3% in 72 patients and the effective half-lives of 131I were 12.0-146.4 h.The thyroid remnant masses were 1.0-6.9 g; absorbed doses were 23-2 197 Gy,and absorbed dose rates at 24 h were 0.5-8.1 Gy/h.No significant difference was observed in absorbed doses to thyroid remnants in 43 patients having successful ablation and 29 patients having unsuccessful ablation ((363± 148) Gy vs (341± 167) Gy,t =15.097,P>0.05).However,the absorbed dose-rates of thyroid remnants at 24 h were significantly higher in patients with successful ablation than those in patients with unsuccessful ablation ((3.7±2.1) Gy/h vs (2.9±1.6) Gy/h,t=7.908,P<0.05).Conclusion A successful ablation is strongly dependent on the absorbed dose-rate of thyroid remnant.
机构地区 [
出处 《中华核医学与分子影像杂志》 CSCD 北大核心 2014年第4期279-282,共4页 Chinese Journal of Nuclear Medicine and Molecular Imaging
基金 国家自然科学基金(81071184) 教育部留学基金(2011624088) 卫生行业科研专项项目子课题(201002002)
关键词 甲状腺肿瘤 放射疗法 碘放射性同位素 辐射剂量 Thyroid neoplasms Radiotherapy Iodine radioisotopes Radiation dosage
  • 相关文献

参考文献16

  • 1Tuttle RM,Tala H,Shah J,et al.Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioac-tive iodine remnant ablation:using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system[J].Thyroid,2010,20:1341-1349.
  • 2张桂芝,谭建,刘雪辉,孟召伟.131I治疗分化型甲状腺癌术后患者疗效影响因素研究[J].中华核医学杂志,2010(4):259-263. 被引量:45
  • 3刘斌,郭佳,王建涛,赵祯,黄蕤,欧晓红,田蓉,匡安仁.^124I PET/CT在分化型甲状腺癌诊治中的应用[J].中华核医学与分子影像杂志,2013,33(1):71-74. 被引量:5
  • 4Bolch WE,Eckerman KF,Sgouros G,et al.MIRD pamphlet No.21:a generalized schema for radiopharmaceutical dosimetry-stand-ardization of nomenclature[ J].J Nucl Med,2009,50:477-484.
  • 5刘斌,赵祯,王建涛,黄蕤,田蓉,曾宇,匡安仁.内照射剂量学指导131I治疗分化型甲状腺癌弥散性肺转移[J].中华核医学杂志,2010,30(6):400-403. 被引量:7
  • 6刘斌,王建涛,牟达,赵祯,黄蕤,田蓉,曾宇,匡安仁.131I治疗分化型甲状腺癌血液和骨髓的吸收剂量及剂量学导向治疗法[J].中华核医学杂志,2010(2):142-144. 被引量:8
  • 7Thisgaard H,Elema DR,Jensen M.Production and dosimetric as-pects of the potent Auger emitter 58mCo for targeted radionuclide therapy of small tumors[ J].Med Phys,2011,38:4535-4541.
  • 8Liu B,Kuang A,Huang R,et al.Influence of vitamin C on sali-vary absorbed dose of 131I in thyroid cancer patients:a prospective,randomized,single-blind,controlled trial[ J].J Nucl Med,2010,51:618-623.
  • 9Liu B,Huang R,Kuang A,et al.Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer[ J].Med Phys,2011,38:5412-5419.
  • 10Taieb D,Sebag F,Farman-Ara B,et al.Iodine biokinetics and ra-dioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal [J].J Clin Endocrinol Metab,2010,95:3283-3290.

二级参考文献46

  • 1Jemal A,Siegel R,Ward E,et al.Cancer statistics,2006.CA Cancer J Clin,2006,56:106-130.
  • 2Sawka AM,Thephamongkhol K,Brouwers M,et al.A systematic review and Meta analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer.J Clin Endocrinol Metab,2004,89:3668-3676.
  • 3Hackshaw A,Harmer C,Mallick U,et al.131Ⅰ activity for remnant ablation in patients with differentied thyroid cancer:a systematic review.J Clin Endocrinol Metab,2007,92:28-38.
  • 4Pacini F,Molinaro E,Castagna MG,et al.Ablation of thyroid residues with 30 mCi 131^I:a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.J Clin Endocrinol Metab,2002,87:4063-4068.
  • 5Doi SAR,Woodhouse NJ,Thalib L,et al.Ablation of the thyroid remnant and 131^I dose in differentiated thyroid cancer:a Meta-analysis revisited.Clin Med Res,2007,5:87-90.
  • 6Benua RS,Cicale NR,Sonenberg M,et al.The relation of radioiodine desimetry to results and complications in treatment of metastatic thyroid cancer.Am J Roentgenol,1962,87:171-182.
  • 7Stabin MG,Brill AB.State of the art in nuclear medicine dose assessment.Semin Nucl Med,2008,38:308-320.
  • 8Lassmann M,Hanscheid H,Chiesa C,et al.EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I:blood and bone marrow dosimetry in differentiated thyroid cancer therapy.Eur J Nucl Med Mol Imaging,2008,35:1405-1412.
  • 9Akabani G,Poston JW.Absorbed dose calculations to blood and blood vessels for internally deposited radionuelides.J Nucl Med,1991,32:830-834.
  • 10Thomas SR,Samaratunga RC,Sperling M,et al.Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer.Nucl Med Biol,1993,20:157-162.

共引文献83

同被引文献65

  • 1StrigariL, KonijnenbergM, ChiesaC, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy[J]. Eur J Nucl Med Mol Imaging, 2014, 41(10):1976-1988. DOI:10.1007/s00259-014-2824-5.
  • 2LiuB, PengW, HuangR, et al. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements[J]. Radiology, 2014, 273(1):211-219. DOI:10.1148/radiol.14132234.
  • 3SmallridgeRC, DiehlN, BernetV. Practice trends in patients with persistent detectable thyroglobulin and negative diagnostic radioiodine whole body scans: a survey of American Thyroid Association members[J]. Thyroid, 2014, 24(10):1501-1507. DOI:10.1089/thy.2014.0043.
  • 4PadovaniRP, KasamatsuTS, NakabashiCC, et al. One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy[J]. Thyroid, 2012, 22(9):926-930. DOI:10.1089/thy.2012.0099.
  • 5LiuB, KuangA, HuangR, et al. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial[J]. J Nucl Med, 2010, 51(4):618-623. DOI:10.2967/jnumed.109.071449.
  • 6LiuB, HuangR, KuangA, et al. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer[J]. Med Phys, 2011, 38(10):5412-5419. DOI:10.1118/1.3602459.
  • 7HoAL, GrewalRK, LeboeufR, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer[J]. N Engl J Med, 2013, 368(7):623-632. DOI:10.1056/NEJMoa1209288.
  • 8JentzenW, HoppenbrouwersJ, van LeeuwenP, et al. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging[J]. J Nucl Med, 2014, 55(11):1759-1765. DOI:10.2967/jnumed.114.144089.
  • 9RaniD, KaisarS, AwasareS, et al. Examining recombinant human TSH primed 131I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol[J]. Eur J Nucl Med Mol Imaging, 2014, 41(9):1767-1780. DOI:10.1007/s00259-014-2737-3.
  • 10PettinatoC, SpeziE, NanniC, et al. Pretherapeutic dosimetry in patients affected by metastatic thyroid cancer using 124I PET/CT sequential scans for 131I treatment planning[J]. Clin Nucl Med, 2014, 39(8):e367-374. DOI:10.1097/RLU.0000000000000490.

引证文献8

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部